Acquisition of Specific Diagnostics by bioMérieux

On April 12th, 2022, bioMérieux acquired Specific Diagnostics, a USA-based company that developed a rapid antimicrobial susceptibility test (AST) system that detects positive blood cultures. bioMérieux has a strong portfolio of diagnostic products that can detect and identify bacterial infections. bioMérieux product line includes BIOFIRE® FILMARRAY®, BACT/ALERT® VIRTUO®, VITEK® MS,…

On April 12th, 2022, bioMérieux acquired Specific Diagnostics, a USA-based company that developed a rapid antimicrobial susceptibility test (AST) system that detects positive blood cultures.

bioMérieux has a strong portfolio of diagnostic products that can detect and identify bacterial infections. bioMérieux product line includes BIOFIRE® FILMARRAY®, BACT/ALERT® VIRTUO®, VITEK® MS, and VITEK® 2, This acquisition definitely helps bioMérieux as they are into this business line for many years and compete more with companies like BD (Becton, Dickinson and Company) and Thermofisher as there is growing importance for the rapid AST testsing.

According to Precision Business Insights, Nosocomial Infections Testing Market is projected to reach close USD 3.5 Billion by 2024. Based on the global estimates, every year around 50 million sepsis cases reported across the globe and 5.4 million deaths every year.

ASIA PACIFIC OFFICE

Precision Business Insights, MIG 366, SAI PLAZA, 1st Floor, KPHB Colony, Hyderabad - 500072

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX